C OSBORNE

TitleDistinguished Service Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
Address7200 CAMBRIDGE
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Molecular & Cellular Biology
    DivisionMolecular & Cellular Biology

    TitleDirector
    InstitutionBaylor College of Medicine
    DepartmentDuncan Cancer Center
    DivisionCancer Center

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDuncan Cancer Center
    DivisionCancer Center


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Falster D, Gallagher R, Wenk EH, Wright IJ, Indiarto D, Andrew SC, Baxter C, Lawson J, Allen S, Fuchs A, Monro A, Kar F, Adams MA, Ahrens CW, Alfonzetti M, Angevin T, Apgaua DMG, Arndt S, Atkin OK, Atkinson J, Auld T, Baker A, von Balthazar M, Bean A, Blackman CJ, Bloomfield K, Bowman DMJS, Bragg J, Brodribb TJ, Buckton G, Burrows G, Caldwell E, Camac J, Carpenter R, Catford JA, Cawthray GR, Cernusak LA, Chandler G, Chapman AR, Cheal D, Cheesman AW, Chen SC, Choat B, Clinton B, Clode PL, Coleman H, Cornwell WK, Cosgrove M, Crisp M, Cross E, Crous KY, Cunningham S, Curran T, Curtis E, Daws MI, DeGabriel JL, Denton MD, Dong N, Du P, Duan H, Duncan DH, Duncan RP, Duretto M, Dwyer JM, Edwards C, Esperon-Rodriguez M, Evans JR, Everingham SE, Farrell C, Firn J, Fonseca CR, French BJ, Frood D, Funk JL, Geange SR, Ghannoum O, Gleason SM, Gosper CR, Gray E, Groom PK, Grootemaat S, Gross C, Guerin G, Guja L, Hahs AK, Harrison MT, Hayes PE, Henery M, Hochuli D, Howell J, Huang G, Hughes L, Huisman J, Ilic J, Jagdish A, Jin D, Jordan G, Jurado E, Kanowski J, Kasel S, Kellermann J, Kenny B, Kohout M, Kooyman RM, Kotowska MM, Lai HR, Laliberté E, Lambers H, Lamont BB, Lanfear R, van Langevelde F, Laughlin DC, Laugier-Kitchener BA, Laurance S, Lehmann CER, Leigh A, Leishman MR, Lenz T, Lepschi B, Lewis JD, Lim F, Liu U, Lord J, Lusk CH, Macinnis-Ng C, McPherson H, Magallón S, Manea A, López-Martinez A, Mayfield M, McCarthy JK, Meers T, van der Merwe M, Metcalfe DJ, Milberg P, Mokany K, Moles AT, Moore BD, Moore N, Morgan JW, Morris W, Muir A, Munroe S, Nicholson Á, Nicolle D, Nicotra AB, Niinemets Ü, North T, O'Reilly-Nugent A, O'Sullivan OS, Oberle B, Onoda Y, Ooi MKJ, Osborne CP, Paczkowska G, Pekin B, Guilherme Pereira C, Pickering C, Pickup M, Pollock LJ, Poot P, Powell JR, Power SA, Prentice IC, Prior L, Prober SM, Read J, Reynolds V, Richards AE, Richardson B, Roderick ML, Rosell JA, Rossetto M, Rye B, Rymer PD, Sams MA, Sanson G, Sauquet H, Schmidt S, Schönenberger J, Schulze ED, Sendall K, Sinclair S, Smith B, Smith R, Soper F, Sparrow B, Standish RJ, Staples TL, Stephens R, Szota C, Taseski G, Tasker E, Thomas F, Tissue DT, Tjoelker MG, Tng DYP, de Tombeur F, Tomlinson K, Turner NC, Veneklaas EJ, Venn S, Vesk P, Vlasveld C, Vorontsova MS, Warren CA, Warwick N, Weerasinghe LK, Wells J, Westoby M, White M, Williams NSG, Wills J, Wilson PG, Yates C, Zanne AE, Zemunik G, Zieminska K. AusTraits, a curated plant trait database for the Australian flora. Sci Data. 2021 09 30; 8(1):254. PMID: 34593819.
      Citations: 2     Fields:    Translation:Animals
    2. Baird AS, Taylor SH, Pasquet-Kok J, Vuong C, Zhang Y, Watcharamongkol T, Scoffoni C, Edwards EJ, Christin PA, Osborne CP, Sack L. Developmental and biophysical determinants of grass leaf size worldwide. Nature. 2021 04; 592(7853):242-247. PMID: 33762735.
      Citations: 4     Fields:    Translation:Animals
    3. Olofsson JK, Dunning LT, Lundgren MR, Barton HJ, Thompson J, Cuff N, Ariyarathne M, Yakandawala D, Sotelo G, Zeng K, Osborne CP, Nosil P, Christin PA. Population-Specific Selection on Standing Variation Generated by Lateral Gene Transfers in a Grass. Curr Biol. 2019 11 18; 29(22):3921-3927.e5. PMID: 31679927.
      Citations: 2     Fields:    Translation:Animals
    4. Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28. PMID: 25587647.
      Citations: 104     Fields:    Translation:Humans
    5. Taylor SH, Ripley BS, Martin T, De-Wet LA, Woodward FI, Osborne CP. Physiological advantages of C4 grasses in the field: a comparative experiment demonstrating the importance of drought. Glob Chang Biol. 2014 Jun; 20(6):1992-2003. PMID: 24677339.
      Citations: 17     Fields:    Translation:AnimalsCells
    6. Lippman M, Osborne CK. Circulating tumor DNA--ready for prime time? N Engl J Med. 2013 Mar 28; 368(13):1249-50. PMID: 23484798.
      Citations: 11     Fields:    Translation:Humans
    7. Li, M.M., Chang, F., Liu, L. , Fang, E., Li, Y., Carmack, C.E., Osborne, C.K. . AGBT. Identification of Clinically Actionable Mutations Using Next Generation Sequencing Technologies – Perspectives from Clinical Diagnostics. 2013.
    8. Contreras, A., Herrera, S., Mayer, I., Forero, A., Nanda, R., Goetz, M., Chang, J., Pavlick, A.C., Fuqua, S.A.W., Gutierrez, C., Li, M.M., Osborne, C.K., Schiff, R., Rimawi, M.F. . SABCS. PIK3CA mutations and / or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab but without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive patients. 2013.
    9. Morrison, G., Fu, X., Shea M., Mitchell, T., Giuliano, M., Osborne, C.K., Klinowska T., Rimawi, M.F., Schiff, R. . SABCS. Therapeutic potential of the dual HER1/2 inhibitor AZD8931 in circumventing endocrine resistance. 2013.
    10. Christin PA, Boxall SF, Gregory R, Edwards EJ, Hartwell J, Osborne CP. Parallel recruitment of multiple genes into c4 photosynthesis. Genome Biol Evol. 2013; 5(11):2174-87. PMID: 24179135.
      Citations: 29     Fields:    Translation:AnimalsCells
    11. Brouckaert O, Paridaens R, Floris G, Rakha E, Osborne K, Neven P. A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Ann Oncol. 2013 Jan; 24(1):47-53. PMID: 22847811.
      Citations: 14     Fields:    Translation:Humans
    12. Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic mirnas as potential biomarkers for malignancy. Int J Cancer. 2012 Nov 15; 131(10):2215-22. PMID: 22618667.
      Citations: 27     Fields:    Translation:HumansCells
    13. Christin PA, Edwards EJ, Besnard G, Boxall SF, Gregory R, Kellogg EA, Hartwell J, Osborne CP. Adaptive evolution of C(4) photosynthesis through recurrent lateral gene transfer. Curr Biol. 2012 Mar 06; 22(5):445-9. PMID: 22342748.
      Citations: 47     Fields:    Translation:AnimalsCells
    14. Rimawi MF, Osborne CK. Breast Cancer: Blocking both driver and escape pathways improves outcomes. Nat Rev Clin Oncol. 2012 Feb 14; 9(3):133-4. PMID: 22330685.
      Citations: 8     Fields:    Translation:Humans
    15. Giuliano, M., Trivedi, M.V., Christiny, P., Zhang, X., Mao, S., Contreras, A., Lewis, M.T., Rimawi, M.F., Osborne, C.K, Schiff, R. . AACR. Circulating tumor cells as a novel model to test efficacy of individualized therapy in breast cancer. 2012.
    16. Kessler, J.D., Kahle, K.T., Sun, T., Meerbrey, K.L., Schlabach, M.R., Schmitt, E., Skinner, S.O., Xu, Q., Li, M.Z., Hartman, Z.C., Rao, M., Yu, P., Dominguez-Vidana, R., Liang, A.C., Solimini, N.L., Bernardi, R.J., Yu, B., Hsu, T., Golding, I., Luo, J., Osborne, C.K., Creighton, C., Hilsenbeck, S.G., Schiff, R., Shaw, C.A., Elledge, S.J., Westbrook, T.F. . AACR. A sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. 2012.
    17. Rimawi, M.F., Aleixo, S., Rozas, A.A., de Matos Neto, J.N., Caleffi, M., Vinholes, J., Figueira, A., Souza, S.C., Reiriz, A.B., Arantes, H., Uttenreuther-Fischer, M. . J Clin Oncol. A neoadjuvant, randomized, open-label Phase II trial of afatinib (A) vs. Trastuzumab (T) vs. Lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). 2012; (30).
    18. Li, M., Wen, Y., Fang, E., Li, Y., Chen, P., Douglas, G., Carmack, C., Osborne, K. . American Society of Human Genetics. Next Generation Sequencing and Chromosomal Microarray Analysis Provide Novel Insight into the Genomic Landscape of Metastatic Breast Cancer. 2012.
    19. Giuliano, M., Wang, Y-C., Gutierrez, C., Rimawi, M.F., Chang J.C., Wang T., Hilsenbeck, S.G., Chamness, G.C., Osborne, C.K., Schiff, R. . SABCS. Parallel upregulation of Bcl2 and estrogen receptor (ER) expression in HER2+ breast cancer patients treated with neoadjuvant lapatinib. 2012.
    20. Fu, X., Kumar, V., Shea, M., Biswal, N.C., Nanda, S., Chayanam, S., Mitchell, T., Meerbrey, K. L., Joshi, A., Westbrook, T.F., Mills, G.B., Creighton, C.J., Hilsenbeck, S.G., Osborne, C.K., Schiff, R. . SABCS. Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors. 2012.
    21. Shou, J., Chew, S.A., Fu, X., Kumar, V., Mitsiades, N., Osborne, C.K., Schiff, R. SABCS. The PKC inhibitor PKC412 antagonizes breast cancer cell growth and enhances tamoxifen sensitivity. 2012.
    22. Margossian, A., Gutierrez, C., May, M., Saadjian, H., Ohanessian, R., Bacigalupo, S., Baravalle, S., Margossian, J., Osborne, C.K., Scheurer, M. . SABCS. Creation of a “state-of-the-art” Breast Cancer Data and Biobank in Argentina. 2012.
    23. Yadav, P., Bhat, R., Chayanam, S., Christiny, P., Nanda, S., Hu, Huizhong, Creighton, C., Osborne, C.K., Schiff, R., Trivedi, M.V. . SABCS. Identification of novel G-protein coupled receptor targets in HER2-positive breast cancer. 2012.
    24. Osborne CK, Evens A. Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting. Oncology (Williston Park). 2011 Dec; 25(14):1422-4, 1426. PMID: 22329194.
      Citations:    Fields:    Translation:Humans
    25. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29; 9(1):16-32. PMID: 22124364.
      Citations: 360     Fields:    Translation:Humans
    26. Glück S, Arteaga CL, Osborne CK. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. Clin Cancer Res. 2011 Sep 01; 17(17):5559-61. PMID: 21764887.
      Citations: 17     Fields:    Translation:HumansCells
    27. Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011 Mar 01; 17(5):1147-59. PMID: 21220480.
      Citations: 75     Fields:    Translation:HumansCellsCTClinical Trials
    28. Jiralerspong, S., Wang, T., Rimawi, M.F., Nangia J.R., Schif R., Giordano, S.H., Pollak, M.N., Chenault, C.C., Osborne, C.K., Hilsenbeck, S.G. . Cancer Res. Obesity, adjuvant therapy and Survival outcomes in early stage breast cancer. 2011; 199s.
    29. Healy, N.A., Creighton, C.J., Fu, X., Tsimelzon, A., Hilesenbeck, S.G., Miller, N., Kerin, M.J., Osborne, C.K., Schiff, R. . . Cancer Res. Identification of miRNAs and their associated target genes involved in endocrine resistance in breast cancer. 2011; 343s.
    30. Covington, K.R., Gu, G., Tsimelzon, A., Hilsenbeck, S., Brown, P., Chang, J., Osborne, C.K., Xu, J., Medina, D., Mangelsdorf, D., Minna, J., Fuqua, S. . AACR. Identification of novel nuclear receptor targets in estrogen receptor negative breast cancer.Identification of novel nuclear receptor targets in estrogen receptor negative breast cancer. 2011.
    31. Chang, J.C.N., Mayer, I.A., Forero-Torres, A., Nanda, R., Goetz, M.P., Rodriguez, A.A., Pavlick, A.C., Wang, T., Hilsenbeck, S.G., Gutierrez, C., Schiff, R., Osborne, C.K., Rimawi, M.F., on behalf of the Translational Breast Cancer Research Consortium (TBCRC); . TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 overexpressing breast cancer. 2011.
    32. Fu, X., Shea, M., Biswal, N.C., Mitchell, T., Giuliano, M., Healy, N.A., Joshi, A., Westbrook, T., Hilsenbeck, S.G., Osborne, C.K., Schiff, R. . SABCS. Establishment and characterization of an endocrine resistance model in vitro and in vivo by inducible PTEN knockdown. 2011.
    33. Morrison, G.D., Fu, X., Ithimakin, S., Rimawi, M.F., Wicha, M.S., Osborne, C.K., Schiff, R. . Cancer Res. Endocrine resistance: Mechanism, tumorigenic capacities and new therapeutic strategies. 2011; 422s.
    34. Fu, X., Shea, M., Biswal, N.C., Mitchell, T., Giuliano, M., Healy, N.A., Meerbrey, K.L., Joshi, A., Westbrook, T., Hilsenbeck, S.G., Osborne, C.K., Schiff, R. . Cancer Res. Establishment and characterization of an endocrine resistance model in vitro and in vivo by inducible PTEN knockdown. 2011; 423s.
    35. Malorni, L., Giuliano, M., Migliaccio, I., Wang, T., Creighton, C.J., Lupien, M., Hilsenbeck, S.G., Healy, N., Mazumdar, A., Trivedi, M.V., Jeselsohn, R., He, H.H., Fu, X., Gutierrez, C., Brown, M., Brown, P.H., Osborne, C.K., Schiff, R. . Cancer Res. AP-1 blockade potentiates the anti-tumor effect of endocrine treatment and reverts the resistant phenotype in hormone receptor-positive breast cancer. 2011; 429s.
    36. Giuliano, M. Christiny, P.I., Zhang, X., Mao, S., Contreras, A., Lewis, M.T., Rimawi, M.F., Osborne, C.K., Schiff, R., Trivedi, M.V. AACR. Identification of triple-negative primary breast cancer xenograft models with high numbers of circulating and disseminated tumor cells. 2011.
    37. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62:233-47. PMID: 20887199.
      Citations: 505     Fields:    Translation:HumansCells
    38. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res. 2010 Dec 15; 16(24):6169-76. PMID: 21169260.
      Citations: 22     Fields:    Translation:Humans
    39. LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R, Cummings SR, Eastell R, Ensrud KE, Goss P, Lee A, Neven P, Reid DM, Curto M, Vukicevic S. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010 Nov 17; 102(22):1706-15. PMID: 21051656.
      Citations: 39     Fields:    Translation:HumansPHPublic Health
    40. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010 Jul; 134(7):e48-72. PMID: 20586616.
      Citations: 400     Fields:    Translation:Humans
    41. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010 Jun; 134(6):907-22. PMID: 20524868.
      Citations: 191     Fields:    Translation:Humans
    42. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 Jun 01; 28(16):2784-95. PMID: 20404251.
      Citations: 1147     Fields:    Translation:Humans
    43. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov; 124(2):433-9. PMID: 20309628.
      Citations: 14     Fields:    Translation:Humans
    44. Malorni, L., Giuliano, M., Migliaccio, I., Healy, N., Wang, T., Creighton, C.J., Lupien, M.,Hilsenbeck, S.G., Healy, N., Mazumdar, A.,Trivedi, M., Jeselsohn, R., He, H.H., Fu, X., Gutierrez C., Brown, M., Brown, P.H., Osborne, C.K., Schiff, R. . AP-1 blockade potentiates the anti-tumor effect of endocrine treatment and reverts the resistant phenotype in hormone receptor-positive breast cancer. 2010.
    45. Fu, X., Wang Y-C., Huang, C., Ward, R.M., Botero, M.F., Shea, M., Hilsenbeck, S.G., Osborne, C.K., Schiff, R. . Plasticity of the ER and HER2 Signaling Networks Results in Compensatory Escape Pathways Contributing to Treatment Resistance. 2010.
    46. Chen, A.C., Migliaccio, I., Gilcrease, M., Osborne, C.K., and Schiff R. SABCS 2010 (page 198S) P2-06-09. Cancer Res. Mucin4 is associated with the Loss of Estrogen-receptor alpha in Breast Cancer. 2010; 198s.
    47. Sun, T., Meerbrey, K.L., Kessler J., Botero, M., Migliaccio, I., Nguyen, D.X., Pavlova, N.N., Bernardi, R.J., Schmitt, E., Hilsenbeck, S.G., Creighton, C.J., Shaw, C.A., Gibbs, R., Wheeler, D., Osborne, C.K., Schiff, R., Elledge, S.J., Westbrook, T.F. . Cancer Res. Identification of a Novel Tumor Suppressor Network Reveals a Role for Proto-Oncogenic Receptor Tyrosine Kinase in Triple-Negative Breast Cancer. 2010; 24:95s.
    48. Oesterreich S., Hilsenbeck, S.G., Skaar, T., Hartmaier, R.J., Flockhart, D.A., Skora, M.J., Osborne, C.K., Rae, J.M. . Correlations between Genetic Variants in CYP2D6 and UGT2B7 and Survival in Breast Cancer Patients Treated with or without Tamoxifen: Results from a Large Cohort Study. 2010.
    49. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65. PMID: 20005174.
      Citations: 502     Fields:    Translation:Humans
    50. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-2063. PMID: 20004966.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    51. Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, Osborne CK, Lyss AP, Hayes DF, Albain KS. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol. 2009 Oct 20; 27(30):4973-9. PMID: 19752340.
      Citations: 16     Fields:    Translation:Humans
    52. Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15; 15(16):5258-66. PMID: 19671875.
      Citations: 19     Fields:    Translation:Humans
    53. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13820-5. PMID: 19666588.
      Citations: 707     Fields:    Translation:HumansCells
    54. Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009 May 01; 27(13):2157-62. PMID: 19307504.
      Citations: 57     Fields:    Translation:Humans
    55. Powles, T., Neven, P., Osborne, C.K., Goss, P., Allred, C., Cummins, S., Wolter, K., Thompson, D., Thompson, R., Armstrong, R., LaCroix, A. . The Breast - St. Gallen. Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women by baseline estradiol levels. 2009.
    56. Albain, K.S., Barlow, W.E., Shak, S., Hortobagyi, G.N., Livingston, R.B., Yeh, I-T., Ravdin, P., Bugarini, R., Baehner, F.L., Davidson, N.E., Sledge, G.W., Winer, E.P., Hudis, C., Ingle, J.N., Perez, E.A., Pritchard, K.I., Shepherd, L., Gralow, J.R., Yoshizawa, C., Allred, D.C., Osborne, C.K., and Hayes, D.F. . SABCS. Prediction of 10-year chemotherapy benefit and breast cancer-specific survival by the 21-gene Recurrence Score (RS) assay in node-positive, ER-positive breast cancer – An update of SWOG-8814 (INT0100). 2009.
    57. Osborne, C.K., Schiff, R. The Breast - St. Gallen. Combine ER and HER-targeted therapy in breast cancer treatment. 2009.
    58. Rodriguez, A.A., Makris, A., Harrison, M.K., Ostler, P.J., Froehlich, A., Pavlick, A., Wong, H., Tsimelzon A., Sexton, K., Hilsenbeck S.G., Lewis, M.T., Rimawi, M., Osborne, C. K., Chang J.C. . Cancer Res. BRCA1 Gene expression signature predicts for anthracycline-chemosensitivity in triple-negative breast cancer. 2009; 2(69):358s.
    59. Wiechman, L.S., Soliz, R., Hilsenbeck., S., Rimawi, M., Osborne, C.K., Schiff, R. . Cancer Res. Combination antiHER therapeutics – efficacy of alternative dosing regimens in ER+/HER2+ breast cancer xenografts. 2009; 2(69):99s.
    60. Migliaccio, I., Gutierrez, C., Wu M-F., Wong, H., Pavlick, A., Hilsenbeck, S.G., Horlings, H.M., Rimawi, M., Berns, K., Bernards, R., Osborne, C.K., Arteaga, C.L. Change, J.C. . Cancer Res. PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpression locally advanced breast cancer. 2009; 2(69):71s.
    61. LaCroix, A.Z., Cummings, S.R., Delmas, P. Eastell, R., Ensrud, K., Reid, D.M., Vukicevic, S., Armstrong, R.A., Thompson, J., Thompson D., Wolter, K., Allred, C., Goss, P., Osborne, C.K., Powles, T.J. 6 . Cancer Res. Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women. 2009; 2(69):66s.
    62. Shou, J., Osborne, C.K., Gee, J.M., Nicholson, R.I., Schiff, R. Cancer Res. Akt-dependent phosphorylation on AIB1serine 967 contributes to breast cancer tamoxifen resistance. 2009; 2(69):740s.
    63. Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99. PMID: 18425577.
      Citations: 41     Fields:    Translation:HumansCells
    64. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33. PMID: 18245484.
      Citations: 215     Fields:    Translation:HumansAnimalsCells
    65. Pandya KJ, Hu P, Osborne CK, Falkson G, Tormey DC. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185). Am J Clin Oncol. 2007 Apr; 30(2):113-25. PMID: 17414459.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    66. Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol. 2007 Feb 20; 25(6):656-61. PMID: 17308269.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    67. Wang LH, Yang XY, Zhang X, An P, Kim HJ, Huang J, Clarke R, Osborne CK, Inman JK, Appella E, Farrar WL. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell. 2006 Dec; 10(6):487-99. PMID: 17157789.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    68. Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9. PMID: 17008703.
      Citations: 74     Fields:    Translation:Humans
    69. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73. PMID: 16912207.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    70. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006 Aug; 98(3):315-27. PMID: 16541323.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    71. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JC. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33. PMID: 16322899.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    72. Hilsenbeck SG, Osborne CK. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s. PMID: 16467123.
      Citations: 2     Fields:    Translation:Humans
    73. Tham YL, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, Elledge RM, Chamness GC, Osborne CK, Allred DC, Chang JC. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84. PMID: 16261403.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    74. Mohsin SK, Allred DC, Osborne CK, Cruz A, Otto P, Chew H, Clark GM, Elledge RM. Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. Breast Cancer Res Treat. 2005 Dec; 94(3):205-11. PMID: 16267611.
      Citations: 2     Fields:    Translation:Humans
    75. Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005 Nov 20; 23(33):8313-21. PMID: 16293862.
      Citations: 38     Fields:    Translation:Humans
    76. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005 Nov; 56 Suppl 1:10-20. PMID: 16273359.
      Citations: 66     Fields:    Translation:HumansCells
    77. Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O'Connell P. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006 Jan; 95(1):7-12. PMID: 16244788.
      Citations: 19     Fields:    Translation:Humans
    78. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005 Oct 20; 23(30):7721-35. PMID: 16234531.
      Citations: 186     Fields:    Translation:HumansCells
    79. Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65. PMID: 16236516.
      Citations: 36     Fields:    Translation:Humans
    80. Jiang S, Meyer R, Kang K, Osborne CK, Wong J, Oesterreich S. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. Mol Endocrinol. 2006 Feb; 20(2):311-20. PMID: 16195251.
      Citations: 29     Fields:    Translation:HumansCells
    81. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005 Sep 07; 97(17):1254-61. PMID: 16145046.
      Citations: 150     Fields:    Translation:HumansCells
    82. Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005 Sep 01; 23(25):5973-82. PMID: 16087950.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    83. Schiff R, Osborne CK. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res. 2005; 7(5):205-11. PMID: 16168139.
      Citations: 28     Fields:    Translation:Humans
    84. Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15; 104(2):236-9. PMID: 15937908.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    85. Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer. 2005 Jul; 12 Suppl 1:S113-7. PMID: 16113087.
      Citations: 15     Fields:    Translation:HumansCells
    86. Osborne CK, Schiff R. Aromatase inhibitors: future directions. J Steroid Biochem Mol Biol. 2005 May; 95(1-5):183-7. PMID: 16019204.
      Citations: 6     Fields:    Translation:Humans
    87. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94. PMID: 15837971.
      Citations: 13     Fields:    Translation:Humans
    88. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005 Mar 10; 23(8):1616-22. PMID: 15755967.
      Citations: 107     Fields:    Translation:HumansCells
    89. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005 Apr 10; 23(11):2469-76. PMID: 15753463.
      Citations: 181     Fields:    Translation:HumansAnimalsCells
    90. Lippman ME, Benz C, Chinnaiyan A, Flockhart D, Harris A, Hudis C, Osborne CK, Press MF, Rae J, Sledge GW, Van't Veer L, Wicha M. Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'. Breast Cancer Res Treat. 2005 Mar; 90(1):1-3. PMID: 15770520.
      Citations:    Fields:    Translation:Humans
    91. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1169-77. PMID: 15718313.
      Citations: 59     Fields:    Translation:Humans
    92. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8. PMID: 15710948.
      Citations: 96     Fields:    Translation:HumansCTClinical Trials
    93. Fuqua SA, Cui Y, Lee AV, Osborne CK, Horwitz KB. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):931-2; author reply 932-3. PMID: 15681552.
      Citations: 15     Fields:    Translation:Humans
    94. Jacob F, Polzin DJ, Osborne CA, Neaton JD, Kirk CA, Allen TA, Swanson LL. Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. J Am Vet Med Assoc. 2005 Feb 01; 226(3):393-400. PMID: 15702689.
      Citations: 32     Fields:    Translation:Animals
    95. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):865s-70s. PMID: 15701879.
      Citations: 134     Fields:    Translation:HumansCells
    96. Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, Lønning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS. Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):861s-4s. PMID: 15701878.
      Citations:    Fields:    Translation:Humans
    97. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9. PMID: 15569979.
      Citations: 67     Fields:    Translation:HumansCells
    98. Pierce LJ, Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston RB, Osborne CK, Albain KS. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005 Jan 01; 23(1):24-9. PMID: 15545669.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    99. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004 Sep 01; 10(17):5670-6. PMID: 15355892.
      Citations: 82     Fields:    Translation:Humans
    100. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35. PMID: 15199112.
      Citations: 399     Fields:    Translation:HumansAnimalsCells
    101. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004 May 01; 22(9):1605-13. PMID: 15117982.
      Citations: 87     Fields:    Translation:HumansCTClinical Trials
    102. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004 Mar; 90 Suppl 1:S2-6. PMID: 15094757.
      Citations: 115     Fields:    Translation:HumansAnimals
    103. Howell A, Osborne CK, Mauriac L. Spreading the word, but not too thinly. Lancet. 2004 Jan 10; 363(9403):165-6. PMID: 14726176.
      Citations:    Fields:    Translation:Humans
    104. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):331S-6S. PMID: 14734488.
      Citations: 138     Fields:    Translation:HumansAnimalsCells
    105. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33. PMID: 14679152.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    106. Osborne CK, Arteaga CL. Role of molecular and genetic markers in breast cancer treatment decisions. J Clin Oncol. 2003 Dec 01; 21(23 Suppl):285s-287s. PMID: 14645413.
      Citations:    Fields:    Translation:Humans
    107. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003 Dec; 12(6):362-7. PMID: 14659106.
      Citations: 36     Fields:    Translation:HumansCells
    108. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9. PMID: 12907009.
      Citations: 193     Fields:    Translation:Humans
    109. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003 Jul 15; 98(2):229-38. PMID: 12872340.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    110. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 03; 349(1):17-26. PMID: 12840088.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    111. Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ, Osborne CK. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer. 2003 Jun; 39(9):1228-33. PMID: 12763210.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    112. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003 May 15; 21(10):1973-9. PMID: 12743151.
      Citations: 186     Fields:    Translation:Humans
    113. Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003 May 15; 63(10):2434-9. PMID: 12750263.
      Citations: 39     Fields:    Translation:Humans
    114. Morrison AJ, Herrera RE, Heinsohn EC, Schiff R, Osborne CK. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol. 2003 Aug; 17(8):1543-54. PMID: 12730327.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    115. Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK, Mauriac L. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003 May; 79(2):207-11. PMID: 12825855.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    116. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006. PMID: 12637463.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    117. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61. PMID: 12618500.
      Citations: 257     Fields:    Translation:HumansCells
    118. Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer. 2003 Jan 01; 97(1):21-9. PMID: 12491501.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    119. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):447S-54S. PMID: 12538499.
      Citations: 100     Fields:    Translation:HumansCells
    120. Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S. PMID: 12538498.
      Citations: 2     Fields:    Translation:Humans
    121. Lu H, Zhang Y, Roberts DD, Osborne CK, Templeton NS. Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. Mol Ther. 2002 Dec; 6(6):783-92. PMID: 12498774.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    122. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9. PMID: 12400010.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    123. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95. PMID: 12177098.
      Citations: 121     Fields:    Translation:HumansCTClinical Trials
    124. Buzdar AU, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS. Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4335s-4337s; discussion 4411s-4412s. PMID: 11916221.
      Citations:    Fields:    Translation:Humans
    125. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s. PMID: 11916222.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    126. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, Lee AV. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res. 2001 Aug 01; 61(15):5771-7. PMID: 11479214.
      Citations: 49     Fields:    Translation:HumansCells
    127. Martin MD, Fischbach K, Osborne CK, Mohsin SK, Allred DC, O'Connell P. Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. Cancer Res. 2001 May 01; 61(9):3578-80. PMID: 11325822.
      Citations: 6     Fields:    Translation:HumansCells
    128. Hartsough MT, Clare SE, Mair M, Elkahloun AG, Sgroi D, Osborne CK, Clark G, Steeg PS. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res. 2001 Mar 01; 61(5):2320-7. PMID: 11280805.
      Citations: 32     Fields:    Translation:HumansCells
    129. Oesterreich S, Allredl DC, Mohsin SK, Zhang Q, Wong H, Lee AV, Osborne CK, O'Connell P. High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer. 2001 Feb; 84(4):493-8. PMID: 11207044.
      Citations: 17     Fields:    Translation:HumansCells
    130. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34. PMID: 11106684.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    131. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000 Sep; 18(17):3172-86. PMID: 10963646.
      Citations: 66     Fields:    Translation:HumansAnimals
    132. Townson SM, Sullivan T, Zhang Q, Clark GM, Osborne CK, Lee AV, Oesterreich S. HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. Clin Cancer Res. 2000 Sep; 6(9):3788-96. PMID: 10999774.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    133. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000 Aug 15; 89(4):817-25. PMID: 10951345.
      Citations: 100     Fields:    Translation:HumansAnimals
    134. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000 Mar 20; 89(2):111-7. PMID: 10754487.
      Citations: 67     Fields:    Translation:HumansCellsCTClinical Trials
    135. Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK, Lee AV. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol. 2000 Mar; 14(3):369-81. PMID: 10707955.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    136. Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK, Dowsett M. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res. 2000 Feb; 6(2):616-21. PMID: 10690547.
      Citations: 28     Fields:    Translation:HumansCells
    137. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999 Oct; 17(10):3058-63. PMID: 10506600.
      Citations: 55     Fields:    Translation:Humans
    138. O'Connell P, Fischbach K, Hilsenbeck S, Mohsin SK, Fuqua SA, Clark GM, Osborne CK, Allred DC. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7. PMID: 10451444.
      Citations: 7     Fields:    Translation:HumansCells
    139. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40. PMID: 10561295.
      Citations: 85     Fields:    Translation:Humans
    140. Osborne CK. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. Endocr Relat Cancer. 1999 Jun; 6(2):271-6. PMID: 10731120.
      Citations: 6     Fields:    Translation:Humans
    141. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999 May; 17(5):1474-81. PMID: 10334533.
      Citations: 652     Fields:    Translation:Humans
    142. Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999 May; 17(5):1442-8. PMID: 10334529.
      Citations: 70     Fields:    Translation:Humans
    143. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96. PMID: 10319328.
      Citations: 104     Fields:    Translation:HumansAnimalsCells
    144. Li S, Chen PL, Subramanian T, Chinnadurai G, Tomlinson G, Osborne CK, Sharp ZD, Lee WH. Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem. 1999 Apr 16; 274(16):11334-8. PMID: 10196224.
      Citations: 45     Fields:    Translation:HumansCells
    145. Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9. PMID: 10070945.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    146. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26; 339(22):1609-18. PMID: 9828250.
      Citations: 318     Fields:    Translation:Humans
    147. Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK, Falkson G. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. J Clin Oncol. 1998 Nov; 16(11):3486-92. PMID: 9817265.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    148. Geyer CE, Green SJ, Moinpour CM, O'Sullivan J, Goodwin DK, Canfield VA, Meyers FJ, Osborne CK, Martino S. Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study. Breast Cancer Res Treat. 1998 Sep; 51(2):169-81. PMID: 9879778.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    149. Fetting JH, Gray R, Fairclough DL, Smith TJ, Margolin KA, Citron ML, Grove-Conrad M, Cella D, Pandya K, Robert N, Henderson IC, Osborne CK, Abeloff MD. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol. 1998 Jul; 16(7):2382-91. PMID: 9667255.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    150. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998 May 06; 90(9):697-703. PMID: 9586667.
      Citations: 75     Fields:    Translation:Humans
    151. Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, Sledge GW, Abeloff MD. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998 May; 16(5):1669-76. PMID: 9586877.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    152. Ciocca DR, Green S, Elledge RM, Clark GM, Pugh R, Ravdin P, Lew D, Martino S, Osborne CK. Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). Clin Cancer Res. 1998 May; 4(5):1263-6. PMID: 9607585.
      Citations: 18     Fields:    Translation:Humans
    153. Diab SG, Hilsenbeck SG, de Moor C, Clark GM, Osborne CK, Ravdin PM, Elledge RM. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60. PMID: 9586875.
      Citations: 12     Fields:    Translation:Humans
    154. Osborne CK, Elledge RM, Brown PH, Hilsenbeck SG. BRCA1 in clinical breast cancer. Breast Dis. 1998 Apr; 10(1-2):77-88. PMID: 15687551.
      Citations:    Fields:    
    155. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998 Apr 01; 82(7):1296-302. PMID: 9529021.
      Citations: 34     Fields:    Translation:Humans
    156. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2920-5. PMID: 9501191.
      Citations: 140     Fields:    Translation:HumansAnimalsCells
    157. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, Robert NJ, Budd GT, Paradelo JC, Natale RB, Bearden JD, Mailliard JA, Osborne CK. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998 Mar; 16(3):994-9. PMID: 9508182.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    158. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37. PMID: 10066085.
      Citations: 58     Fields:    Translation:HumansCells
    159. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998; 51(3):227-38. PMID: 10068081.
      Citations: 116     Fields:    Translation:Humans
    160. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998 Jan; 4(1):7-12. PMID: 9516946.
      Citations: 30     Fields:    Translation:Humans
    161. Clark GM, Osborne CK, Levitt D, Wu F, Kim NW. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997 Dec 17; 89(24):1874-81. PMID: 9414175.
      Citations: 22     Fields:    Translation:HumansCells
    162. Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8. PMID: 9407959.
      Citations: 15     Fields:    Translation:HumansAnimals
    163. Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res. 1997 Sep 01; 57(17):3723-7. PMID: 9288779.
      Citations: 8     Fields:    Translation:HumansAnimals
    164. Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, Martino S, Osborne CK. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol. 1997 Jul; 15(7):2494-501. PMID: 9215817.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    165. Elledge RM, Osborne CK. Oestrogen receptors and breast cancer. BMJ. 1997 Jun 28; 314(7098):1843-4. PMID: 9224112.
      Citations: 14     Fields:    Translation:Humans
    166. Van den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng CN, McDermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB, Yee D. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997 Jun; 33(7):1108-13. PMID: 9376191.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    167. Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, Trott PA, Ashley SE, Ormerod MG, Titley JC, Osborne CK. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat. 1997 May; 44(1):65-74. PMID: 9164679.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    168. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol. 1997 May; 15(5):1916-22. PMID: 9164202.
      Citations: 35     Fields:    Translation:HumansCells
    169. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997 Apr; 3(4):593-600. PMID: 9815725.
      Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
    170. Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr; 43(2):153-63. PMID: 9131271.
      Citations: 13     Fields:    Translation:HumansCells
    171. Albain KS, Green SR, Lichter AS, Hutchins LF, Wood WC, Henderson IC, Ingle JN, O'Sullivan J, Osborne CK, Martino S. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996 Nov; 14(11):3009-17. PMID: 8918499.
      Citations: 29     Fields:    Translation:Humans
    172. Osborne CK. Aromatase inhibitors in the treatment of advanced breast cancer. Introduction. Semin Oncol. 1996 Aug; 23(4 Suppl 9):1. PMID: 8824458.
      Citations:    Fields:    Translation:Humans
    173. Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SA. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206. PMID: 9816288.
      Citations: 8     Fields:    Translation:Humans
    174. Osborne CK, Coronado-Heinsohn E. Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF). Cancer J Sci Am. 1996 May-Jun; 2(3):175-80. PMID: 9166518.
      Citations: 1     Fields:    Translation:HumansCells
    175. Nicholson RI, Gee JM, Bryant S, Francis AB, McClelland RA, Knowlden J, Wakeling AE, Osborne CK. Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann N Y Acad Sci. 1996 Apr 30; 784:325-35. PMID: 8651581.
      Citations: 1     Fields:    Translation:Humans
    176. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson NO, Sevelda P. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet. 1996 Apr 20; 347(9008):1066-71. PMID: 8602056.
      Citations: 19     Fields:    Translation:Humans
    177. Chen Y, Chen PL, Riley DJ, Lee WH, Allred DC, Osborne CK. Response: Location of BRCA1 in Human Breast and Ovarian Cancer Cells. Science. 1996 Apr 05; 272(5258):125-6. PMID: 17789966.
      Citations: 9     Fields:    
    178. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92. PMID: 9816207.
      Citations: 24     Fields:    Translation:HumansCells
    179. Rivkin SE, Green S, O'Sullivan J, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Osborne CK. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1996 Jan; 14(1):46-51. PMID: 8558219.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    180. Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Von Hoff D, Osborne CK, Lee WH. Aberrant subcellular localization of BRCA1 in breast cancer. Science. 1995 Nov 03; 270(5237):789-91. PMID: 7481765.
      Citations: 68     Fields:    Translation:HumansCells
    181. Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FM. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11. PMID: 7573366.
      Citations: 54     Fields:    Translation:Humans
    182. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst. 1995 Aug 16; 87(16):1254-6. PMID: 7563172.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    183. Katzenellenbogen JA, Coleman RE, Hawkins RA, Krohn KA, Larson SM, Mendelsohn J, Osborne CK, Piwnica-Worms D, Reba RC, Siegel BA, et al. Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. Clin Cancer Res. 1995 Aug; 1(8):921-32. PMID: 9816063.
      Citations: 6     Fields:    Translation:Humans
    184. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50. PMID: 7563152.
      Citations: 68     Fields:    Translation:HumansAnimals
    185. Rønne E, Høyer-Hansen G, Brünner N, Pedersen H, Rank F, Osborne CK, Clark GM, Danø K, Grøndahl-Hansen J. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat. 1995 Mar; 33(3):199-207. PMID: 7749147.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    186. Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK. Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ. 1994 Dec; 5(12):1275-82. PMID: 7696176.
      Citations: 12     Fields:    Translation:HumansCells
    187. Fabian CJ, Kimler BF, McKittrick R, Park CH, Lin F, Krishnan L, Jewell WR, Osborne CK, Martino S, Hutchins LF, et al. Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study. Cancer Res. 1994 Oct 15; 54(20):5357-62. PMID: 7923165.
      Citations: 1     Fields:    Translation:HumansCells
    188. Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994 Oct; 12(10):2078-85. PMID: 7931477.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    189. Osborne CK. Current trials and future directions of the Southwest Oncology Group Breast Cancer Committee. Cancer. 1994 Aug 01; 74(3 Suppl):1135-8. PMID: 8039149.
      Citations:    Fields:    Translation:Humans
    190. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994 May 04; 86(9):705-12. PMID: 7908990.
      Citations: 120     Fields:    Translation:HumansCells
    191. Stein D, Wu J, Fuqua SA, Roonprapunt C, Yajnik V, D'Eustachio P, Moskow JJ, Buchberg AM, Osborne CK, Margolis B. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994 Mar 15; 13(6):1331-40. PMID: 7907978.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    192. Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SA, Hilsenbeck SH, Chamness GC, Osborne CK. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74. PMID: 8120545.
      Citations: 7     Fields:    Translation:Humans
    193. Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK. Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat. 1994; 32(1):105-12. PMID: 7819579.
      Citations: 9     Fields:    Translation:Humans
    194. LeMaistre CF, Meneghetti C, Howes L, Osborne CK. Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat. 1994; 32(1):97-103. PMID: 7819590.
      Citations: 10     Fields:    Translation:HumansAnimals
    195. Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994; 32(1):67-71. PMID: 7819588.
      Citations: 18     Fields:    Translation:Humans
    196. Allred DC, O'Connell P, Fuqua SA, Osborne CK. Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat. 1994; 32(1):13-8. PMID: 7819582.
      Citations: 14     Fields:    Translation:Humans
    197. O'Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat. 1994; 32(1):5-12. PMID: 7819586.
      Citations: 28     Fields:    Translation:Humans
    198. Osborne CK, Chamness GC. Translational research in the San Antonio breast cancer SPORE. Breast Cancer Res Treat. 1994; 32(1):1-4. PMID: 7819578.
      Citations: 2     Fields:    Translation:Humans
    199. Osborne CK, Fuqua SA. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat. 1994; 32(1):49-55. PMID: 7819585.
      Citations: 25     Fields:    Translation:HumansAnimals
    200. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol. 1994; 34(2):89-95. PMID: 8194171.
      Citations: 18     Fields:    Translation:AnimalsCells
    201. Osborne CK, Sunderland MC, Neidhart JA, Ravdin PM, Abeloff MD. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. Ann Oncol. 1994 Jan; 5(1):43-7. PMID: 8172792.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    202. Atiba JO, Green SJ, Hynes HE, Osborne CK, Miller TP, Davidner M. Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1994; 12(2):129-32. PMID: 7860229.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    203. Osborne CK. Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol. 1993 Dec; 47(1-6):83-9. PMID: 8274445.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    204. Hayden KA, Moinpour CM, Metch B, Feigl P, O'Bryan RM, Green S, Osborne CK. Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum. 1993 Oct; 20(9):1415-9. PMID: 8265446.
      Citations: 7     Fields:    Translation:Humans
    205. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res. 1993 Oct 01; 53(19):4443-8. PMID: 8402609.
      Citations: 75     Fields:    Translation:HumansCells
    206. Rivkin SE, Green S, Metch B, Jewell WR, Costanzi JJ, Altman SJ, Minton JP, O'Bryan RM, Osborne CK. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol. 1993 Sep; 11(9):1710-6. PMID: 8355037.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    207. van de Pasch T. [An orientation toward caregiving]. TVZ. 1993 Jun 24; (12):393. PMID: 8397840.
      Citations:    Fields:    Translation:Humans
    208. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 03; 85(3):200-6. PMID: 8423624.
      Citations: 207     Fields:    Translation:Humans
    209. Encarnación CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26(3):237-46. PMID: 8251648.
      Citations: 57     Fields:    Translation:Humans
    210. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992 Sep; 23(9):974-9. PMID: 1355464.
      Citations: 91     Fields:    Translation:Humans
    211. Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1992 Jul 01; 52(13):3636-41. PMID: 1617636.
      Citations: 21     Fields:    Translation:HumansCells
    212. Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol. 1992 Jun; 10(6):990-4. PMID: 1588380.
      Citations: 23     Fields:    Translation:HumansAnimals
    213. Elledge RM, McGuire WL, Osborne CK. Prognostic factors in breast cancer. Semin Oncol. 1992 Jun; 19(3):244-53. PMID: 1351692.
      Citations: 19     Fields:    Translation:Humans
    214. Osborne CK. Prognostic factors for breast cancer: have they met their promise? J Clin Oncol. 1992 May; 10(5):679-82. PMID: 1569440.
      Citations: 10     Fields:    Translation:Humans
    215. Clark GM, Mathieu MC, Owens MA, Dressler LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff MD, et al. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol. 1992 Mar; 10(3):428-32. PMID: 1740681.
      Citations: 14     Fields:    Translation:HumansCells
    216. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol. 1992 Feb; 10(2):304-10. PMID: 1732430.
      Citations: 31     Fields:    Translation:HumansCells
    217. Osborne CK. Polypeptide growth factors: their potential value in the management of breast cancer patients. Cancer Treat Res. 1992; 60:315-29. PMID: 1355995.
      Citations:    Fields:    Translation:Humans
    218. Dressler LG, Eudey L, Gray R, Tormey DC, McGuire WL, Gilchrist KW, Clark GM, Osborne CK, Mansour EG, Abeloff MD. Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). J Natl Cancer Inst Monogr. 1992; (11):167-72. PMID: 1627424.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    219. Osborne CK, Blumenstein BA, Crawford ED, Weiss GR, Bukowski RM, Larrimer NR. Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur J Cancer. 1992; 28(2-3):477-8. PMID: 1591066.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    220. Mansour EG, Eudey L, Tormey DC, Shatila AH, Osborne CK, Gilchrist KW, Cooper MR, Falkson G. Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992; (11):97-104. PMID: 1627437.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    221. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24(2):85-95. PMID: 8095168.
      Citations: 184     Fields:    Translation:HumansAnimalsCells
    222. Albain KS, Green S, LeBlanc M, Rivkin S, O'Sullivan J, Osborne CK. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat. 1992; 22(3):273-84. PMID: 1391993.
      Citations: 3     Fields:    Translation:Humans
    223. Osborne CK. Dose intensity as a therapeutic strategy in breast cancer. Breast Cancer Res Treat. 1991 Dec; 20 Suppl:S11-4. PMID: 1687202.
      Citations: 1     Fields:    Translation:Humans
    224. Osborne CK. Hematopoietic growth factors in breast cancer--overview. Breast Cancer Res Treat. 1991 Dec; 20 Suppl:S1-2. PMID: 1806028.
      Citations:    Fields:    Translation:Humans
    225. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst. 1991 Oct 16; 83(20):1477-82. PMID: 1920493.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    226. Budd GT, Green S, Baker LH, Hersh EP, Weick JK, Osborne CK. A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer. 1991 Oct 15; 68(8):1694-5. PMID: 1913510.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    227. Cowan JD, Neidhart J, McClure S, Coltman CA, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Aug 07; 83(15):1077-84. PMID: 1875415.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    228. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 1991 Jul; 9(7):1283-97. PMID: 2045868.
      Citations: 17     Fields:    Translation:Humans
    229. Reddy KB, Yee D, Osborne CK. Rapid identification of transfected plasmid expression vectors in cells by PCR. Biotechniques. 1991 Apr; 10(4):481-2, 484. PMID: 1867857.
      Citations:    Fields:    Translation:Humans
    230. Von Hoff DD, Green SJ, Neidhart JA, Fabian C, Budd T, Boyd JF, Osborne CK. Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1991 Feb; 9(1):87-8. PMID: 2026487.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    231. Arteaga CL, Osborne CK. Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. Cancer Treat Res. 1991; 53:289-304. PMID: 1672083.
      Citations: 10     Fields:    Translation:HumansCells
    232. Osborne CK, Clemmons DR, Arteaga CL. Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol. 1990 Dec 20; 37(6):805-9. PMID: 2178363.
      Citations: 15     Fields:    Translation:HumansCells
    233. Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology. 1990 Dec; 127(6):2679-86. PMID: 1701124.
      Citations: 22     Fields:    Translation:HumansCells
    234. Osborne CK, Blumenstein B, Crawford ED, Coltman CA, Smith AY, Lambuth BW, Chapman RA. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol. 1990 Oct; 8(10):1675-82. PMID: 2213104.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    235. Osborne CK, Arteaga CL. Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat. 1990 Jan; 15(1):3-11. PMID: 2183891.
      Citations: 18     Fields:    Translation:Humans
    236. Merkel DE, Osborne CK. Prognostic factors in breast cancer. Hematol Oncol Clin North Am. 1989 Dec; 3(4):641-52. PMID: 2558104.
      Citations: 9     Fields:    Translation:Humans
    237. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989 Nov 15; 49(22):6237-41. PMID: 2553250.
      Citations: 45     Fields:    Translation:HumansCells
    238. Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SA, Ramasharma K, Marshall M, Li CH. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol. 1989 Nov; 3(11):1701-9. PMID: 2558302.
      Citations: 55     Fields:    Translation:Cells
    239. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC, Allred DC, Osborne CK. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989 Nov; 84(5):1418-23. PMID: 2553774.
      Citations: 90     Fields:    Translation:HumansAnimalsCells
    240. McGuire WL, Johnson PA, Muss HB, Osborne CK. Megestrol acetate in breast cancer--a panel discussion. Breast Cancer Res Treat. 1989 Oct; 14(1):33-8. PMID: 2605342.
      Citations:    Fields:    Translation:Humans
    241. Osborne CK. DNA flow cytometry in early breast cancer: a step in the right direction. J Natl Cancer Inst. 1989 Sep 20; 81(18):1344-5. PMID: 2778818.
      Citations: 3     Fields:    Translation:Humans
    242. Liu E, Santos G, Lee WM, Osborne CK, Benz CC. Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. Oncogene. 1989 Aug; 4(8):979-84. PMID: 2668848.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    243. Osborne CK, Craig JB, Klein K, Crawford ED, Turner J. Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer. Invest New Drugs. 1989 Jul; 7(2-3):243-5. PMID: 2793381.
      Citations:    Fields:    Translation:Humans
    244. Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol. 1989 Jun; 7(6):710-7. PMID: 2715802.
      Citations: 22     Fields:    Translation:HumansCells
    245. McGuire WL, Abeloff MD, Fisher B, Glick JH, Henderson IC, Osborne CK. Adjuvant therapy in node-negative breast cancer. A panel discussion. Breast Cancer Res Treat. 1989 Mar; 13(2):97-115. PMID: 2659105.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    246. Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, Cooper MR, Falkson G. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989 Feb 23; 320(8):485-90. PMID: 2915651.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    247. Dorr RT, Liddil JD, Von Hoff DD, Soble M, Osborne CK. Antitumor activity and murine pharmacokinetics of parenteral acronycine. Cancer Res. 1989 Jan 15; 49(2):340-4. PMID: 2910453.
      Citations: 5     Fields:    Translation:AnimalsCells
    248. Merkel DE, Osborne CK. Adjuvant treatment of node-negative breast cancer. Tex Med. 1989 Jan; 85(1):32-6. PMID: 2922686.
      Citations:    Fields:    Translation:Humans
    249. DeGregorio MW, Coronado E, Osborne CK. Tumor and serum tamoxifen concentrations in the athymic nude mouse. Cancer Chemother Pharmacol. 1989; 23(2):68-70. PMID: 2910513.
      Citations: 6     Fields:    Translation:Animals
    250. Osborne CK. Cell proliferative indices and DNA content as prognostic factors in primary breast cancer. Horm Res. 1989; 32 Suppl 1:238-41. PMID: 2613209.
      Citations: 1     Fields:    Translation:Humans
    251. Robert NJ, Dalton WS, Osborne CK, Abeloff M. Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. Horm Res. 1989; 32 Suppl 1:221-2. PMID: 2533155.
      Citations: 1     Fields:    Translation:Humans
    252. McGuire WL, Foley KM, Levy MH, Osborne CK. Pain control in breast cancer. A panel discussion. Breast Cancer Res Treat. 1989 Jan; 13(1):5-15. PMID: 2565124.
      Citations:    Fields:    Translation:Humans
    253. Arteaga CL, Coronado E, Osborne CK. Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol. 1988 Nov; 2(11):1064-9. PMID: 3221874.
      Citations: 26     Fields:    Translation:HumansCells
    254. McGuire WL, Dickson RB, Osborne CK, Salomon D. The role of growth factors in breast cancer. A panel discussion. Breast Cancer Res Treat. 1988 Oct; 12(2):159-66. PMID: 3242646.
      Citations: 4     Fields:    Translation:Humans
    255. Arteaga CL, Hanauske AR, Clark GM, Osborne CK, Hazarika P, Pardue RL, Tio F, Von Hoff DD. Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. Cancer Res. 1988 Sep 01; 48(17):5023-8. PMID: 3165707.
      Citations: 15     Fields:    Translation:Humans
    256. Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK. Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res. 1988 Jul 15; 48(14):3898-904. PMID: 3164252.
      Citations: 53     Fields:    Translation:HumansCells
    257. Osborne CK, Ross CR, Coronado EB, Fuqua SA, Kitten LJ. Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model. Breast Cancer Res Treat. 1988 Jul; 11(3):211-9. PMID: 3167228.
      Citations: 6     Fields:    Translation:HumansAnimals
    258. Brünner N, Osborne CK, Spang-Thomsen M. Endocrine therapy of human breast cancer grown in nude mice. Breast Cancer Res Treat. 1987 Dec; 10(3):229-42. PMID: 3328985.
      Citations: 6     Fields:    Translation:HumansAnimals
    259. Osborne CK, Coronado EB, Robinson JP. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol. 1987 Aug; 23(8):1189-96. PMID: 3653212.
      Citations: 49     Fields:    Translation:HumansAnimals
    260. Hanauske AR, Osborne CK, Chamness GC, Clark GM, Forseth BJ, Buchok JB, Arteaga CL, Von Hoff DD. Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol. 1987 May; 23(5):545-51. PMID: 3498632.
      Citations: 6     Fields:    Translation:HumansCells
    261. DeGregorio MW, Wilbur BJ, Coronado E, Osborne CK. Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration. Cancer Chemother Pharmacol. 1987; 20(4):316-8. PMID: 3690805.
      Citations: 8     Fields:    Translation:Animals
    262. McGuire WL, Lippman ME, Osborne CK, Thompson EB. Resistance to endocrine therapy. A panel discussion. Breast Cancer Res Treat. 1987; 9(3):165-73. PMID: 3663953.
      Citations: 1     Fields:    Translation:Humans
    263. Clark GM, Sledge GW, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987 Jan; 5(1):55-61. PMID: 3806159.
      Citations: 73     Fields:    Translation:Humans
    264. Osborne CK, Hobbs K, Trent JM. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat. 1987; 9(2):111-21. PMID: 3620713.
      Citations: 63     Fields:    Translation:HumansAnimalsCells
    265. Osborne CK, Coltman CA. Adjuvant chemotherapy. CA Cancer J Clin. 1986 Jan-Feb; 36(1):59-60. PMID: 3080209.
      Citations:    Fields:    Translation:Humans
    266. Osborne CK, Rivkin SE, McDivitt RW, Green S, Stephens RL, Costanzi JJ, O'Bryan R. Adjuvant therapy of breast cancer: Southwest Oncology Group studies. NCI Monogr. 1986; (1):71-4. PMID: 3534592.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    267. Graham KA, Trent JM, Osborne CK, McGrath CM, Minden MD, Buick RN. The use of restriction fragment polymorphisms to identify the cell line MCF-7. Breast Cancer Res Treat. 1986; 8(1):29-34. PMID: 3790748.
      Citations: 4     Fields:    Translation:HumansCells
    268. Rivkin SE, Knight WA, McDivitt R, Cruz T, Foulkes M, Osborne CK, Fabian CJ, Costanzi JJ. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. J Steroid Biochem. 1985 Dec; 23(6B):1151-4. PMID: 3912621.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    269. Rivkin SE, Knight WA, McDivitt R, Cruz T, Foulkes M, Osborne CK, Fabian CJ, Costanzi JJ. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. World J Surg. 1985 Oct; 9(5):723-7. PMID: 3840629.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    270. Rivkin SE, Glucksberg H, Foulkes M, Osborne CK, Tranum W, Gad-el-Mawla N, Constanzi J. Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM. World J Surg. 1985 Oct; 9(5):719-22. PMID: 3840628.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    271. Osborne CK. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol. 1985 Sep; 12(3):317-26. PMID: 3901267.
      Citations: 13     Fields:    Translation:Humans
    272. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985 Feb; 45(2):584-90. PMID: 3967234.
      Citations: 108     Fields:    Translation:HumansAnimalsCells
    273. Osborne CK, Von Hoff DD, Mullins K. Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay. Breast Cancer Res Treat. 1985; 6(3):229-35. PMID: 2936413.
      Citations: 4     Fields:    Translation:HumansCells
    274. Cowan JD, Osborne CK, Neidhart JA, Von Hoff DD, Constanzi JJ, Vaughn CB. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Invest New Drugs. 1985; 3(2):149-52. PMID: 3894277.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    275. Coltman CA, Osborne CK. Bisantrene, biological and clinical effects. Cancer Treat Rev. 1984 Dec; 11(4):285-8. PMID: 6534510.
      Citations: 2     Fields:    Translation:HumansAnimals
    276. Osborne CK. Hormone receptors in the management of breast cancer. Tex Med. 1984 Nov; 80(11):30-2. PMID: 6515569.
      Citations:    Fields:    Translation:Humans
    277. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984 Oct; 2(10):1102-9. PMID: 6491696.
      Citations: 97     Fields:    Translation:Humans
    278. Gross GE, Boldt DH, Osborne CK. Perturbation by insulin of human breast cancer cell cycle kinetics. Cancer Res. 1984 Aug; 44(8):3570-5. PMID: 6378371.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    279. Osborne CK, Boldt DH, Estrada P. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res. 1984 Apr; 44(4):1433-9. PMID: 6704960.
      Citations: 22     Fields:    Translation:HumansCells
    280. Osborne CK, Von Hoff DD, Cowan JD, Sandbach J. Bisantrene, an active drug in patients with advanced breast cancer. Cancer Treat Rep. 1984 Feb; 68(2):357-60. PMID: 6697324.
      Citations: 8     Fields:    Translation:Humans
    281. Osborne CK, Drelichman A, Von Hoff DD, Crawford ED. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep. 1983 Dec; 67(12):1133-5. PMID: 6652630.
      Citations: 4     Fields:    Translation:Humans
    282. Ibbotson KJ, D'Souza SM, Ng KW, Osborne CK, Niall M, Martin TJ, Mundy GR. Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science. 1983 Sep 23; 221(4617):1292-4. PMID: 6577602.
      Citations: 35     Fields:    Translation:AnimalsCells
    283. Osborne CK, Boldt DH, Clark GM, Trent JM. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res. 1983 Aug; 43(8):3583-5. PMID: 6861130.
      Citations: 67     Fields:    Translation:HumansCells
    284. Garvin AJ, Simon RM, Osborne CK, Merrill J, Young RC, Berard CW. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer. 1983 Aug 01; 52(3):393-8. PMID: 6344979.
      Citations: 19     Fields:    Translation:HumansCells
    285. Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA, McGuire WL. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983 Jan; 43(1):413-6. PMID: 6847780.
      Citations: 44     Fields:    Translation:Humans
    286. Myers JW, Von Hoff DD, Kuhn JG, Osborne CK, Sandbach JF, Pocelinko R. Anaphylactoid reactions associated with bisantrene infusions. Invest New Drugs. 1983; 1(1):85-8. PMID: 6678858.
      Citations: 4     Fields:    Translation:Humans
    287. Monaco ME, Osborne CK, Bronzert TJ, Kidwell WR, Lippman ME. Characterization of insulin regulation of lipid synthesis in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1983; 3(3):279-85. PMID: 6367855.
      Citations:    Fields:    Translation:HumansCells
    288. McGuire WL, Osborne CK, Clark GM, Knight WA. Steroid hormone receptors and carcinoma of the breast. Am J Physiol. 1982 Aug; 243(2):E99-102. PMID: 7114210.
      Citations: 16     Fields:    Translation:Humans
    289. Hubbard SM, Chabner BA, DeVita VT, Simon R, Berard CW, Jones RB, Garvin AJ, Canellos GP, Osborne CK, Young RC. Histologic progression in non-Hodgkin's lymphoma. Blood. 1982 Feb; 59(2):258-64. PMID: 7034812.
      Citations: 21     Fields:    Translation:Humans
    290. Elson DL, Osborne CK, Livingston RB, Von Hoff DD. Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition. Stem Cells. 1982; 2(1):34-44. PMID: 7157082.
      Citations: 1     Fields:    Translation:HumansCells
    291. Suarez AJ, Lamm DL, Radwin HM, Sarosdy M, Clark G, Osborne CK. Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer Chemother Pharmacol. 1982; 8(3):261-5. PMID: 7127658.
      Citations: 6     Fields:    Translation:Humans
    292. Osborne CK, Hamilton B, Nover M, Ziegler J. Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells. J Clin Invest. 1981 Apr; 67(4):943-51. PMID: 6259217.
      Citations: 8     Fields:    Translation:HumansCells
    293. Osborne CK, Fisher E, Redmond C, Knight WA, Yochmowitz MG, McGuire WL. Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis. Adv Exp Med Biol. 1981; 138:377-85. PMID: 7342719.
      Citations: 4     Fields:    Translation:Humans
    294. Knight WA, Clark GM, Osborne CK, McGuire WL. Adjuvant therapy for stage II, estrogen receptor negative breast cancer. Breast Cancer Res Treat. 1981; 1(2):131-4. PMID: 7348569.
      Citations:    Fields:    Translation:Humans
    295. Osborne CK. Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat. 1981; 1(2):121-3. PMID: 7348568.
      Citations: 6     Fields:    Translation:Humans
    296. Von Hoff DD, Sandbach J, Osborne CK, Metelmann C, Clark GM, O'Brien M. Potential and problems with growth of breast cancer in a human tumor cloning system. Breast Cancer Res Treat. 1981; 1(2):141-8. PMID: 7348571.
      Citations: 2     Fields:    Translation:HumansCells
    297. Fisher ER, Osborne CK, McGuire WL, Redmond C, Knight WA, Fisher B, Bannayan G, Walder A, Gregory EJ, Jacobsen A, Queen DM, Bennett DE, Ford HC. Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat. 1981; 1(1):37-41. PMID: 7348564.
      Citations: 16     Fields:    Translation:Humans
    298. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15; 46(12 Suppl):2884-8. PMID: 7448733.
      Citations: 160     Fields:    Translation:Humans
    299. Osborne CK, Knight WA, Yochmowitz MG, McGuire WL. Modern approaches to the treatment of breast cancer. Blood. 1980 Nov; 56(5):745-52. PMID: 7426746.
      Citations: 4     Fields:    Translation:Humans
    300. Knight WA, Osborne CK, Yochmowitz MG, McGuire WL. Steroid hormone receptors in the management of human breast cancer. Ann Clin Res. 1980 Oct; 12(5):202-7. PMID: 7015982.
      Citations: 14     Fields:    Translation:Humans
    301. Osborne CK, Norton L, Young RC, Garvin AJ, Simon RM, Berard CW, Hubbard S, DeVita VT. Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. Blood. 1980 Jul; 56(1):98-103. PMID: 6992889.
      Citations: 6     Fields:    Translation:Humans
    302. Knight WA, Osborne CK, McGuire WL. Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab. 1980 Jul; 9(2):361-8. PMID: 6249524.
      Citations: 7     Fields:    Translation:HumansCells
    303. Osborne CK, Hamilton B, Titus G, Livingston RB. Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res. 1980 Jul; 40(7):2361-6. PMID: 6966967.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    304. Gaskill SP, McGuire WL, Osborne CK, Stern MP. Breast cancer mortality and diet in the United States. Cancer Res. 1979 Sep; 39(9):3628-37. PMID: 582576.
      Citations: 7     Fields:    Translation:HumansAnimals
    305. Osborne CK, Monaco ME, Kahn CR, Huff K, Bronzert D, Lippman ME. Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. Cancer Res. 1979 Jul; 39(7 Pt 1):2422-8. PMID: 445441.
      Citations: 12     Fields:    Translation:HumansCells
    306. Osborne CK, McGuire WL. Therapy for cancer of the breast. Current status of steroid hormone receptors. West J Med. 1979 May; 130(5):401-7. PMID: 516664.
      Citations:    Fields:    Translation:Humans
    307. Osborne CK, McGuire WL. The use of steroïd hormone receptors in the treatment of human breast cancer: a review. Bull Cancer. 1979; 66(3):203-9. PMID: 385079.
      Citations: 11     Fields:    Translation:Humans
    308. Osborne CK, McGuire WL. Current use of steroid hormone receptor assays in the treatment of breast cancer. Surg Clin North Am. 1978 Aug; 58(4):777-88. PMID: 684560.
      Citations: 5     Fields:    Translation:HumansCells
    309. Osborne CK, Monaco ME, Lippman ME, Kahn CR. Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res. 1978 Jan; 38(1):94-102. PMID: 22400.
      Citations: 35     Fields:    Translation:HumansCells
    310. Monaco ME, Osborne CK, Lippman ME. Insulin stimulation of fatty acid synthesis in human breast cancer cells. J Natl Cancer Inst. 1977 Jun; 58(6):1591-3. PMID: 559098.
      Citations: 3     Fields:    Translation:HumansCells
    311. Lippman ME, Osborne CK, Knazek R, Young N. In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med. 1977 Jan 20; 296(3):154-9. PMID: 187935.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    312. Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A. 1976 Dec; 73(12):4536-40. PMID: 1070004.
      Citations: 72     Fields:    Translation:HumansCells
    313. Woolley PV, Osborne CK, Levi JA, Wiernik PH, Canellos GP. Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer. 1976 Aug; 38(2):1026-35. PMID: 788888.
      Citations: 4     Fields:    Translation:Humans
    314. Osborne CK, Carolla R, Jefferson D, Mengel CE. Effect of methemoglobin on in vivo RBC lipid peroxidation. Aerosp Med. 1973 Jan; 44(1):63-7. PMID: 4689488.
      Citations: 1     Fields:    Translation:AnimalsCells
    315. Osborne CK, Brubaker LH, Mengel CE. Effects of hyperoxia on white blood cells. I. In vivo changes in the total white blood cell counts of normal rats. Aerosp Med. 1970 Oct; 41(10):1176-9. PMID: 5458201.
      Citations:    Fields:    Translation:AnimalsCells
    OSBORNE's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (714)
    Explore
    _
    Co-Authors (20)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _